- Home
- PETS vs ANIX Comparison
PETS vs ANIX Comparison
Compare PETS & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | ANIX |
|---|---|---|
| Founded | 1996 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.7M | 135.3M |
| IPO Year | N/A | 1987 |
Fundamental Metrics
Financial Performance| Metric | PETS | ANIX |
|---|---|---|
| Price | $3.90 | $3.61 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.20 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 6.9M | 353.5K |
| Earning Date | 02-02-2026 | 01-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $226,972,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.57 | $2.07 |
| 52 Week High | $6.08 | $5.46 |
Technical Indicators
Market Signals| Indicator | PETS | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 80.75 | 38.82 |
| Support Level | $1.69 | $4.20 |
| Resistance Level | $4.05 | $5.46 |
| Average True Range (ATR) | 0.34 | 0.44 |
| MACD | 0.24 | -0.16 |
| Stochastic Oscillator | 92.49 | 14.05 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.